| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Departments of Pediatrics and Immunology, University of Toronto, The Hospital For Sick Children, Research Institute, Toronto, Ontario, Canada; and
Department of Pediatrics, University of Pittsburgh, Children’s Hospital, Pittsburgh, PA 15213
An anergic phenotype has been observed in nonobese diabetic (NOD) mice and some autoreactive T cells from patients with type I diabetes. To better understand this phenomenon, we measured T cell proliferative responses to 10 diabetes-associated and up to 9 control Ags/peptides in 148 new diabetic children, 51 age- and MHC (DQ)-matched siblings (sibs), 31 patients with longstanding diabetes, and 40 healthy controls. Most (78–91%) patient and sib responses to glutamate decarboxylase of 65 kDa (GAD65), islet cell cytoplasmic autoantibody (ICA) 69, diabetes-associated T cell epitopes in ICA69 (Tep69), and heat shock protein (Hsp) 60 involved anergic T cells that required exogenous IL-2 to proliferate. Responses to proinsulin, IA-2 (and tetanus toxoid) required no IL-2 and generated sufficient cytokine to rescue anergic T cell responses. Most new patients (85%) had autoreactive T cells, three quarters targeting more than half of the diabetes Ags. Only 7.8% of the sibs and none of the controls had such multiple T cell autoreactivities, which thus characterize overt disease. Multiple anergic and nonanergic T cell autoreactivities were sustained during 2 yr follow-up after onset and in patients with longstanding (3–26 yr) diabetes. Activated patient T cells survived severe IL-2 deprivation, requiring 20–100 times less IL-2 than normal T cells to escape apoptosis. Diabetic T cell anergy thus persists for decades and is Ag and host specific but not related to disease course. Rescue by IL-2 from bystander T cells and high resistance to apoptosis may contribute to this persistence. These data explain some of the difficulties in the routine detection of disease-associated T cells, and they emphasize challenges for immunotherapy and islet transplantation.
This article has been cited by other articles:
|
|
 |
|
  H. Tsui, Y. Chan, L. Tang, S. Winer, R. K. Cheung, G. Paltser, T. Selvanantham, A. R. Elford, J. R. Ellis, D. J. Becker, et al. Targeting of Pancreatic Glia in Type 1 Diabetes Diabetes, April 1, 2008; 57(4): 918 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. U. A. Mollah, S. Pai, C. Moore, B. J. O'Sullivan, M. J. Harrison, J. Peng, K. Phillips, J. B. Prins, J. Cardinal, and R. Thomas Abnormal NF-{kappa}B Function Characterizes Human Type 1 Diabetes Dendritic Cells and Monocytes J. Immunol., March 1, 2008; 180(5): 3166 - 3175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mallone, E. Martinuzzi, P. Blancou, G. Novelli, G. Afonso, M. Dolz, G. Bruno, L. Chaillous, L. Chatenoud, J.-M. Bach, et al. CD8+ T-Cell Responses Identify {beta}-Cell Autoimmunity in Human Type 1 Diabetes Diabetes, March 1, 2007; 56(3): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Seyfert-Margolis, T. D. Gisler, A. L. Asare, R. S. Wang, H. M. Dosch, B. Brooks-Worrell, G. S. Eisenbarth, J. P. Palmer, C. J. Greenbaum, S. E. Gitelman, et al. Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 Diabetes: Results of a Blinded Controlled Study Diabetes, September 1, 2006; 55(9): 2588 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Alvarez-Lara, J. Carracedo, R. Ramirez, A. Martin-Malo, M. Rodriguez, J. A. Madueno, and P. Aljama The imbalance in the ratio of Th1 and Th2 helper lymphocytes in uraemia is mediated by an increased apoptosis of Th1 subset Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3084 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fritsch, D. Eselbock, K. Skriner, B. Jahn-Schmid, C. Scheinecker, B. Bohle, M. Tohidast-Akrad, S. Hayer, J. Neumuller, S. Pinol-Roma, et al. Characterization of Autoreactive T Cells to the Autoantigens Heterogeneous Nuclear Ribonucleoprotein A2 (RA33) and Filaggrin in Patients with Rheumatoid Arthritis J. Immunol., July 15, 2002; 169(2): 1068 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Winer, I. Astsaturov, R. Gaedigk, D. Hammond-McKibben, M. Pilon, A. Song, V. Kubiak, W. Karges, E. Arpaia, C. McKerlie, et al. ICA69null Nonobese Diabetic Mice Develop Diabetes, but Resist Disease Acceleration by Cyclophosphamide J. Immunol., January 1, 2002; 168(1): 475 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Winer, I. Astsaturov, R. K. Cheung, K. Schrade, L. Gunaratnam, D. D. Wood, M. A. Moscarello, P. O'Connor, C. McKerlie, D. J. Becker, et al. T Cells of Multiple Sclerosis Patients Target a Common Environmental Peptide that Causes Encephalitis in Mice J. Immunol., April 1, 2001; 166(7): 4751 - 4756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Winer, I. Astsaturov, R. K. Cheung, L. Gunaratnam, V. Kubiak, M. A. Cortez, M. Moscarello, P. W. O'Connor, C. McKerlie, D. J. Becker, et al. Type I Diabetes and Multiple Sclerosis Patients Target Islet Plus Central Nervous System Autoantigens; Nonimmunized Nonobese Diabetic Mice Can Develop Autoimmune Encephalitis J. Immunol., February 15, 2001; 166(4): 2831 - 2841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Winer, L. Gunaratnam, I. Astsatourov, R. K. Cheung, V. Kubiak, W. Karges, D. Hammond-McKibben, R. Gaedigk, D. Graziano, M. Trucco, et al. Peptide Dose, MHC Affinity, and Target Self-Antigen Expression Are Critical for Effective Immunotherapy of Nonobese Diabetic Mouse Prediabetes J. Immunol., October 1, 2000; 165(7): 4086 - 4094. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
